At a glance
ClinicalIndex Comparison RecordN/ACompleted· 10 enrolled
Drug / intervention
Not specified
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Oral Cladribine B-cell Study
In Brief
An observational study for Multiple Sclerosis. Completed, enrolled 10 participants across 1 site.
Detailed Summary
To study the impact of cladribine on peripheral and intrathecal B-cell, plasma cells, T cells and Tregs
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsMultiple Sclerosis
CountriesUnited Kingdom
Collaborators--
Timeline
N/ACompletedFinished
2020202120222023202420252026
Enrollment StartJul 2019
Primary CompletionJan 2024
First PostedMay 2024
TodayJul 2026
First PostedMay 16, 2024
Enrollment StartJul 1, 2019
Primary CompletionJan 31, 2024
TodayJul 2, 2026
Enrollment to primary: 4.6 yearsPosted 2.1 years ago